The integration of computational chemistry during drug discovery to drive decisions: are we there yet?-Reference-Cited by-同舟云学术

The integration of computational chemistry during drug discovery to drive decisions: are we there yet?

Published:2016-09 Issue:14 Volume:8 Page:1717-1720
ISSN:1756-8919
Container-title:Future Medicinal Chemistry
language:en
Short-container-title:Future Medicinal Chemistry

Author:

Desai Prashant V¹

Affiliation:

1. Computational ADME, Drug Disposition, Eli Lilly & Company, Indianapolis, IN 46285, USA

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Link

http://www.future-science.com/doi/pdf/10.4155/fmc-2016-0161

Reference8 articles.

1. Armstrong D, Coons C. Lilly turns from one company veteran to another for new CEO.Bloomberg News (2016). www.bloomberg.com/news/articles/2016–07–27/lilly-ceo-lechleiter-to-retire-will-be-replaced-by-david-ricks.

2. Computational medicinal chemistry

3. Advances in Computational Medicinal Chemistry: A Reflection on the Evolution of the Field and Perspective Going Forward

4. Predictive DMPK: In Silico ADME Predictions in Drug Discovery

5. Pushing the boundaries of computational approaches: special focus issue on computational chemistry and computer-aided drug discovery

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico development of novel angiotensin-converting-enzyme-I inhibitors by Monte Carlo optimization based QSAR modeling, molecular docking studies and ADMET predictions;Computational Biology and Chemistry;2024-10

2. Design, in silico Evaluation, and Determination of Antitumor Activity of Potential Inhibitors Against Protein Kinases: Application to BCR-ABL Tyrosine Kinase;Biochemistry (Moscow);2024-06